News | 23 February 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Appoints Dr Rafiq Hasan as CEO
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The companies plan to use the proceeds to retire debt and expand operations
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Subscribe To Our Newsletter & Stay Updated
